In triple negative breast cancer, SLCO1A2 encodes organic anion-transporting polypeptide 1A2 (OA TP1A2), and the expression of OATP1A2 and organic cation transporter 6 was predicted to be an indicator of response to neoadjuvant chemotherapy (Hashimoto et al., 2014). Here, SLC22A16 is linked to triple-negative breast carcinoma.